

Original Research Article

“To assess the clinical efficacy and safety of oral Terbinafine, Fluconazole and Itraconazole in the treatment of tinea corporis in a tertiary care hospital”.

Abstract:

Context: Comparing the three drugs for its safety and efficacy.

Aims: This study was aimed to assess the clinico-mycological efficacy and safety of oral terbinafine, fluconazole and itraconazole in the treatment of tinea corporis in a tertiary care hospital.

Study Design: This is a Randomised comparative study with a sample size of 60 patients.

Methods and Material: Patients were enrolled after considering various inclusion and exclusion criteria into three groups. Group A (oral Terbinafine 250mg daily for 2 weeks), group B (Fluconazole 150mg once weekly for 2 weeks) and group C (Itraconazole 200mg once daily for 2 weeks). Clinical assessment was performed weekly on the basis of physician global assessment grading the severity of pruritus, erythematic, vesicle and desquamation.

Statistical analysis used: Paired t- test was used to calculate the statistical significance between the pre and post interventional results. The software used was SPSS version 20.

Results: Of the 60 patients, 51 completed the study on comparison between the three groups terbinafine (n=15), itraconazole (n=18) and fluconazole (n=18), it was observed that terbinafine was more effective on pruritis (80%), erythema (40%) and desquamation (80%). Itraconazole showed effectiveness on vesicle (66.66%).

Conclusions: Terbinafine was better than itraconazole and fluconazole in relieving signs and symptoms during the study period.

Key-words: Desquamation, Erythema, Fluconazole, Itraconazole, Terbinafine, Tinea.

Key Message: Safety and efficacy studies plays a very pivotal role in avoiding the resistance of the drugs among patients. According to this study, Terbinafine was more effective than Itraconazole and Fluconazole in alleviating clinical signs and symptoms particularly in pruritus, erythema and desquamation, whereas Itraconazole was found effective in relieving vesicle.

Introduction:

Dermatophytosis infection represents a superficial infection of the keratinized layers of hair, nail and skin caused by dermatophytic fungi.¹ Dermatophytosis in India have received increasing attention in recent years from different parts of the country. This study was undertaken to evaluate the clinico-mycological efficacy of three drugs Fluconazole, Itraconazole and Terbinafine in Tinea Corporis and to evaluate the susceptibility of isolates to the three antifungal drugs.

Topical agents such as clotrimazole are usually well tolerated and penetrate into the systemic circulation infrequently. However, topical agents may not penetrate well into the keratin barrier, and thus may not provide optimal treatment for dermatophyte infections located within the keratin. Furthermore, topical agents may induce irritant or allergic contact dermatitis, and repeated application to extensive areas of skin is not always practical for patients. For these reasons, a desirable alternative for the treatment of dermatophyte infections is an oral agent with proven efficacy and minimal toxicity.²

Subjects and Methods:

A Randomised comparative study was conducted from August 2015- March 2016. Ethical approval for the study was obtained from the local Ethics Committee. 60 untreated patients with diagnosis of tinea corporis were selected. Patients who fulfilled the selection criteria were briefed about the nature of study and a written informed consent was obtained. All the patients > 16years of age with the diagnosis of tinea corporis were selected. Patients with severe dermatophytosis and with involvement of more than 15% body surface area were excluded. Patients already on antifungal therapy or those who used oral fungals and antibiotics 14 days of baseline were also excluded. Pregnant women and patients with hepatic or renal disease were also not included.

Study Design:

A detailed history was taken regarding duration and progress of lesion in past and demographic details including family history, age, and sex in a predesigned Performa. A complete dermatological examination was done to assess type of lesion, morphology and distribution was done along with general physical examination. Relevant systemic

63 examination was done and the findings were recorded along with the vital examination of the
64 subject. The affected area was first thoroughly cleaned with 70% alcohol to remove surface
65 contaminants. After the alcohol dried, skin scraping was collected from the border of the
66 active lesion using a microscopic slide, moving the slide perpendicular to the skin surface
67 where another slide was kept along to collect the specimen sample. Specimen was collected
68 on sterile paper.

69 Samples of the patients were subjected to necessary investigations which include KOH test,
70 culture test.

71 Clinical assessment was performed on the basis of global physician assessment by scoring
72 the severity of pruritus, erythematic, vesicle and desquamation from 1 to 3 (3=severe,
73 2=moderate, 1=mild 1=absent).

74 Diary for safety assessment was provided to the patients of both groups and patients were
75 explained all the details about diary and trained to fill the diary. Patients were also provided
76 with Patient Information Leaflet (PIL) in the language which was understandable to them.

77 *First Visit*

78 Patients were screened and thus allotted the Group of treatment.

79 *Randomization*

80 Patients will be randomly assigned to three groups Group1, Group 2 and Group3 through
81 Simple Randomization method.

82 (I) GROUP A (Daily Oral Terbinafine)

83 In this group patients were given oral Terbinafine (250 mg) daily at morning time after
84 breakfast for 2 weeks.

85 (II) GROUP B (Weekly Oral Fluconazole)

86 In this group patients were given oral Fluconazole (150 mg) once weekly at morning time
87 after breakfast for 2 weeks.

88 (III) GROUP C (Daily Oral Itraconazole)

89 In this group patients were given oral Itraconazole (200mg) once daily at morning time after
90 breakfast for 2 weeks.

91 *Follow up and Evaluation*

92 Patients were followed at 2nd week and 3rd week (after the end of treatment) wherein
93 physical clinical assessment was performed in all their visits.

94 *Statistical Analysis:*

95 Once the data was collected ANOVA Fisher exact p test was used for data analysis

96 **Results:**

97 The present study was carried out in a tertiary care hospital over a period of six months. All
98 clinically diagnosed cases of Tinea Corporis in the age groups above 16 years old and of
99 both sexes, attending the outpatient department of Dermatology and Venereology were
100 taken for the study and patients who were already on treatment with antifungals and
101 antibiotics or dermatophytosis were excluded from the study.


102 In our study we had 60 T.corporis patients enrolled with *T.rubrum* as the most common
103 isolate.

104 The data obtained was coded and entered into Microsoft excel spreadsheet and
105 analyzed. The results and observations were as below:

106

107 *Figure 1: Sex Wise Distribution of Cases*

108



109


110

111 Our study showed that the Incidence of Tinea Corporis was high in males than females
112 with the male to female ratio of 13:7.

113

114 *Figure 2: Commonly involved age group in the study*

115




116

117

118 In the study, most common age group with Tinea Corporis patients was 60-70 years
 119 comprised of 23.33%.The Distribution of other age groups is shown in Graph.


120

121 **Figure 3: Occupation**



In the study most of the patients were Farmers (33%) followed by housewives (30%). The occupation of other patients is shown in Graph.

Figure 4: KOH Status of Clinical samples



In the study KOH examination for fungus was positive in 48% of the cases and negative for 12% cases.

133 *Table 1: Comparison of Baseline Demographics*

GENDER		
	FEMALE/MALE	TOTAL PATIENTS
FLUCONAZOLE	4/14	18
TERBINAFINE	8/7	15
ITRACONAZOLE	6/12	18
	p= 0.173	

134

AGE		
	MEAN±SD	RANGE
FLUCONAZOLE	45.6±18.34	17-66
TERBINAFINE	38.8±14.38	23-73
ITRACONAZOLE	40.1±17.95	17-71
	p= 0.473	

135

136 *Table 2: Comparison of changes in proportion with Pruritus*

137

BASELINE VISIT			
DRUGS	GRADE		TOTAL PATIENTS(n)
	3	4	
FLUCONAZOLE	8 (44.44%)	10 (55.55%)	18
TERBINAFINE	9 (60%)	6 (40%)	15
ITRACONAZOLE	8 (44.44%)	10 (55.55%)	18
	p=0.091		

138

VISIT 2				
DRUGS	GRADE			TOTAL PATIENTS(n)
	2	3	4	
FLUCONAZOLE	3 (16.66%)	12 (66.66)	3 (16.66)	18
TERBINAFINE	8 (53.33%)	7 (46.66%)	0	15
ITRACONAZOLE	4 (22.22%)	13 (72.22%)	1 5.55%)	18
TOTAL	p=0.599			


139

VISIT 3				
DRUGS	GRADE			TOTAL PATIENTS(n)
	1	2	3	
FLUCONAZOLE	0	9 (50%)	9 (50%)	18
TERBINAFINE	12 (80%)	3 (20%)	0	15
ITRACONAZOLE	4 (22.22%)	9 (50%)	5 (27.77%)	18
TOTAL	16	21	14	51
	p=0.001			

140

141

142 *Figure 5: Comparison of changes in proportion with Pruritus*



143

144

145

146

147

148

149

150

151

152 *Table 3: Comparison of changes in proportion with erythema*

153

BASELINE VISIT					
DRUGS	GRADE				TOTAL PATIENTS(n)
	1	2	3	4	
FLUCONAZOLE	1 (5.55%)	4 (22.22%)	10(55.55%)	3(16.66%)	18
TERBINAFINE	2(13.33%)	2 (13.33%)	7 (46.66%)	4 (26.22%)	15
ITRACONAZOLE	2(11.11%)	1(5.55%)	12(66.66%)	3(16.66%)	18
	p=0.765				
VISIT 2					
DRUGS	GRADE			TOTAL PATIENTS(n)	
	1	2	3		
FLUCONAZOLE	2 (11.11%)	5 (27.7%)	11 (61.11%)	18	
TERBINAFINE	4 (26.66%)	6(40%)	5(33.33%)	15	
ITRACONAZOLE	2(11.11%)	13(72.22%)	3(16.66%)	18	
	p=0.035				
VISIT 3					
DRUGS	GRADE			TOTAL PATIENTS(n)	
	1	2	3		
FLUCONAZOLE	8 (44.44%)	8 (44.44%)	4 (22.22%)	18	
TERBINAFINE	8 (53.33%)	6 (40%)	1 (6.66%)	15	
ITRACONAZOLE	6 (33.33%)	11(61.11%)	1 (5.55%)	18	
	p=0.435				

154

155

156

157

158

159

160

161

Figure 6: Comparison of changes in proportion with erythema




Table 4: Comparison of changes in proportion with vesicles


BASELINE VISIT					
DRUGS	GRADE				TOTAL PATIENTS(n)
	1	2	3	4	
FLUCONAZOLE	3 (16.66%)	9(50%)	5(27.77%)	1(5.55%)	18
TERBINAFINE	7(46.66%)	5(33.33%)	3(20%)	0	15
ITRACONAZOLE	2(11.11%)	9(50%)	7(38.88%)	0	18
	p=0.221				
VISIT 2					
DRUGS	GRADE			TOTAL PATIENTS(n)	
	1	2	3		
FLUCONAZOLE	8(44.44%)	7(38.88%)	3(16.66%)	18	
TERBINAFINE	12(80%)	3(20%)	0	15	
ITRACONAZOLE	7(38.88%)	10(55.55%)	1(5.55%)	18	
	p=0.075				
VISIT 3					
DRUGS	GRADE			TOTAL	

	1	2	PATIENTS(n)
FLUCONAZOLE	13(72.22%)	5(27.77%)	18
TERBINAFINE	15(100%)	0	15
ITRACONAZOLE	14(77.77%)	4(22.22%)	18
	p=0.072		

167

168 *Figure 7: Comparison of changes in proportion with vesicles*

169



170

171

172 *Table 5: Comparison of changes in proportion with Desquamation*

173


BASELINE VISIT					
DRUGS	GRADE				TOTAL
	1	2	3	4	PATIENTS(n)
FLUCONAZOLE	1(5.55%)	5(27.77%)	10(55.55%)	2(11.11%)	18
TERBINAFINE	1(6.66%)	3(20%)	11(73.33%)	0	15
ITRACONAZOLE	1(5.55%)	8(44.44%)	8(44.44%)	1(5.55%)	18
	p=0.498				
VISIT 2					
DRUGS	GRADE			TOTAL	
	1	2	3	PATIENTS(n)	

FLUCONAZOLE	1(5.55%)	15(83.33%)	2(11.11%)	18
TERBINAFINE	4(26.66%)	10(66.66%)	1(6.66%)	15
ITRACONAZOLE	8(44.44%)	8(44.44%)	2(11.11%)	18
	p=0.066			
VISIT 3				
DRUGS	GRADE			TOTAL PATIENTS(n)
	1	2	3	
FLUCONAZOLE	10(55.55%)	6(33.33%)	2(11.11%)	18
TERBINAFINE	13(86.66%)	2(13.33%)	0	15
ITRACONAZOLE	12(66.66%)	6(33.33%)	0	18
	p=0.276			

174

175 *Figure 8: Comparison of changes in proportion with Desquamation*

176



177

178

179

180

181

Discussion:

Considering the facts the present study was conducted to know the clinical efficacy of three antifungal drugs i.e, Terbinafine, Itraconazole and Fluconazole with respect to understanding the disease pattern which thereby relates to clinical efficacy of the above drugs.

In the present study males were more affected. Almost two third patients (65%) were males with a male to female ratio of 1.85:1.

There was lesser variation in the male to female ratio among previous studies. A study conducted in Farukkabad, Uttar Pradesh Amit Kumar et al reported male to female ratio of 1.36:1 in 2013.³

In contrast, Bindu V et al from Vishakapatnam reported almost wide variation distribution of the disease in both the genders with a male to female ratio 2.06:1.⁴

Overall the previous studies including present study observed male population is commonly greater which may be due to the increased sweating and active workload outdoors.⁵

In this study maximum age group patients belonged to the age 61-70yrs old (25%) with next common age groups from 21-30yrs old (23.33%).

Study conducted by C.Roopa and Sunil Kumar Biradar in Raichur Karnataka in 2012 where maximum number of cases encountered in the age group 31-40yrs (47.27%) followed by 21-30yrs (29.09%).⁶

In our study the maximum number of patients were in the age group 61-70yrs, it may be due to the higher incidence of dermatophytes in those patients proportional to the hygienic conditions, amount of sebum production and decreased immunity with old age.⁷

Occupation distribution among the patients in the study was widely varied with maximum number of patients being farmers (33.33%) followed by housewives (30%) to a lesser extent of students (15%). Overall present study observed farmers being subjected to this disease is on higher incidence which may be due to outdoor activity and excessive sweating to that of housewives because all the female patients were housewives and prevalence may be due to wet conditions or humidity.⁸ In the present study maximum cases were noted from September to November (65%) with peak in the month of November. The higher incidence is during or post rainy days which may be due to humidity or moisture.

214

215 Change in pruritus was seen at the end of treatment phase with the comparison on the
216 grades from baseline to visit 3 (V-3).It was noted that there were no patients with grade1 (G-
217 1) at baseline visit and visit 2 (V-2).Whereas in V-3 there were 0% of patients treated with
218 Fluconazole, 80% of patients treated with Terbinafine and 22.22% patients treated with
219 Itraconazole. Therefore it is significant that Terbinafine was very effective in curing pruritus.

220

221 At the end of treatment phase the proportion of erythema was effectively cured to G-1 from
222 13.33% in baseline visit to 53.33% in V-3 with an effectiveness by 40 % in Terbinafine group
223 followed by Fluconazole 38.89% effectiveness. Thus Terbinafine being effective in curing
224 erythema.

225

226 At the baseline visit vesicle in the Itraconazole group 11.11% of patients were at G-1 which
227 was significantly increased to 77.77 % with an effectiveness of 66.66% to that of Terbinafine
228 group which showed 53.34% increase in resolution in G-1.Thus our study showing
229 Itraconazole being effective in curing vesicle.

230

231 Comparison of effectiveness in G-1 for desquamation Terbinafine showed clinical
232 improvement in G-1 from 6.66% in baseline visit to 86.66% in V-3 with overall effectiveness
233 of 80%.

234 In a study conducted by Deval N Vora et al in Gujarat, reported that there was no significant
235 difference in between terbinafine and itraconazole in terms of clinical cure where therapy of
236 terbinafine v/s itraconazole, clinical cure rate (>70%) were 79% and 82% respectively.⁹
237 Furthermore a study conducted by E. Arca et al reported a clinical evaluation, where
238 endpoint of the follow-up period, the clinical cure rates were 81.3% (13/16) in the terbinafine
239 group, 77.8% (14/18) in the itraconazole group, and 37.5% (6/16) in the fluconazole group.¹⁰

240 Hence the studies show that Terbinafine being more effective followed by Itraconazole and
241 Fluconazole.

242

243 **Whats known:**

244

Topical agents may not penetrate well into the keratin barrier, and thus may not provide optimal treatment for dermatophyte infections located within the keratin. A desirable alternative for the treatment of dermatophyte infections is an oral agent with proven efficacy and minimal toxicity.

What's new: Our study correlated the differential of grading of pruritus, erythema, vesicle and desquamation. As per our knowledge no direct comparison of Terbinafine, Itraconazole and Fluconazole was studied for tinea corporis with respect to pruritus, erythema, vesicle and desquamation.

Limitations: This study involved small sample size where the study can have a larger sample size if conducted for a longer duration which may also have more number of dermatophyte isolates which may have been studied for the efficacy of the drugs.

Conclusion: The result of this study indicates that Terbinafine was more effective than Itraconazole and Fluconazole in alleviating clinical signs and symptoms particularly in pruritus, erythema and desquamation, whereas Itraconazole was found effective in relieving vesicle. Fluconazole was seen as to be least effective in relieving the symptoms. None of the patients complained any contact dermatitis or adverse reaction to the drug suggesting excellent safety and tolerability of Terbinafine, Itraconazole and Fluconazole.

FUTURE DIRECTIONS

Comparison of added antifungals agents can be included in further studies for better safety and efficacy of various drugs. Subjects with multiple clinical diagnosis of tinea can be included in further studies. Comparison of oral and topical antifungals can be studied with respect to relapse of the infection.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity.

Ethical approval

Ethical approval for the study was obtained from the KLE University's Ethics Committee.

Financial support and sponsorship

Nil.

REFERENCES

1. Marais, Andre & Osuch, Elzbieta. Common cutaneous dermatophyte infections of the skin and nails. South African Family Practice. 2017; 59, 33-40.
2. Bart C, Antonio P, Bent S, S Slawomir, Wojciech S. Comparision of efficacy and safety of oral fluconazole and topical clotrimazole in the treatment of tinea corporis, tinea cruris, tinea pedis and cutaneous candidiasis. [Current Therapeutic Research](#). 1998; 59(7), 503-510
3. Amit K, Navin B, Priyamvada S, Monika S. A comparative study of efficacy of terbinafine and fluconazole in patients of tinea corporis. International journal of biomedical research. 2013; 04 (11)
4. Bindu V, Pavithran K. Clinico-mycological study of dermatophytosis in Calicut. Indian Journal of Dermatology, Venereology, and Leprology. 2002; 68(5):259.
5. Kanwar AJ, Chander MJ. Superficial fungal infections. In: IADVL Textbook and Atlas of Dermatology. 2001. Vol. 1, ed. 2
6. Roopa C, Biradar S. Incidence and Speciation of Coagulase Negative Staphylococcus Isolates from Clinically Relevant Specimens with their Antibiotic Susceptibility Patterns. Int. J. Curr. Microbiol. App. Sci. 2015; 4(9):975-80.
7. Burns T, Breathnach S, Cox N, Griffiths C. Rooks textbook of dermatology. London: Blackwell Publishing; 2003. 7th ed.,
8. Youngchim S, Pornsuwan S, Nosanchuk JD, Dankai W, Vanittanakom N. Melanogenesis in dermatophyte species *in vitro* and during infection. *Microbiology*. 2011; 157(8):2348-2356.

- 310 9. Deval NV et al. Oral antifungals in treatment of Onychomycosis. Journal of Research
311 in Medical and Dental Science 2014; 2(4)
- 312 10. E. Arca, H. B. Taştan, A. Akar, Z. Kurumlu & A. R. Gür. An open, randomized,
313 comparative study of oral fluconazole, itraconazole and terbinafine therapy in
314 onychomycosis, Journal of Dermatological Treatment. 2014; 13(1), 3-9.